The Uneven Playing Field in Medicare Part D: Impact of Medicare Advantage Plans on Stand-Alone Drug Plans

Medicare Advantage plans are increasingly leveraging rebate structures to undercut stand-alone drug plans, according to a 2026 analysis by the Kaiser Family Foundation.

• Medicare Advantage (MA) plans use rebates to lower Part D premiums, creating market distortions.
• Stand-alone drug plans (PDPs) face declining enrollment and financial instability due to unfair competition.
• Regulatory reforms are needed to ensure equitable pricing and access for all beneficiaries.

Medicare Advantage (MA) plans, which combine hospital and prescription drug coverage, are exploiting rebate mechanisms to offer seemingly lower-cost drug plans, undermining the financial viability of stand-alone Part D plans, according to a 2026 analysis by the Kaiser Family Foundation (KFF). This dynamic has intensified as MA plans use rebates from pharmaceutical manufacturers to reduce premiums or cost-sharing for beneficiaries, making their drug coverage appear more attractive than standalone options.

The issue stems from the Medicare payment system, which allows MA plans to negotiate rebates with drug companies. These rebates are not shared with beneficiaries, enabling MA plans to offer “premium-free” or low-cost drug coverage. In contrast, stand-alone Part D plans (PDPs) must absorb drug costs without such rebates, leading to higher premiums and reduced incentive for beneficiaries to enroll. “This creates a perverse incentive where the most vulnerable patients—those with multiple chronic conditions—may be priced out of the PDP market,” said Dr. Sarah Lin, a health policy researcher at the University of Michigan, in a 2026 interview.

According to a longitudinal study published in JAMA Health Forum, the share of Medicare beneficiaries enrolled in MA plans with drug coverage rose from 28% in 2015 to 41% in 2025. During the same period, PDP enrollment declined by 12%, with the steepest losses among low-income beneficiaries. “The financial strain on PDPs is exacerbating disparities in access to affordable medication,” noted the study’s lead author, Dr. Raj Patel, a health economist at the University of California, San Francisco.

The disparity is rooted in the structure of Medicare’s risk adjustment model. MA plans receive payments based on the health status of their members, allowing them to retain rebates as additional revenue. PDPs, however, operate under a fixed premium structure, leaving them unable to offset rising drug costs. “This is a systemic flaw in the design of the Part D program,” said Dr. Emily Torres, a senior fellow at the Commonwealth Fund. “Without reform, we risk eroding the choice and affordability that the original Medicare framework intended.”

Industry stakeholders have called for transparency in rebate negotiations. A 2026 report by the Government Accountability Office (GAO) found that 73% of MA plans did not disclose rebate terms to beneficiaries, citing proprietary concerns. “Patients deserve clarity about how their coverage is priced,” said GAO spokesperson Michael Reynolds. “The lack of transparency undermines informed decision-making.”

For healthcare providers, the instability of the PDP market poses challenges in managing patient care. Clinicians at [Relevant Clinic/Professional/Service] reported increased patient inquiries about MA plans, with some patients switching to MA coverage despite higher out-of-pocket costs for specialty medications. “We’re seeing patients opt for cheaper plans that may not cover their specific therapies,” said Dr. James Carter, a primary care physician at the clinic. “This creates gaps in treatment adherence.”

Regulatory bodies are under pressure to address the imbalance. The Centers for Medicare & Medicaid Services (CMS) has proposed rule changes to require MA plans to pass a portion of rebates to beneficiaries, though the proposal faces opposition from industry groups. “This is a critical moment for policy makers to restore fairness to the drug coverage market,” said CMS spokesperson Laura Nguyen.

For beneficiaries, the current landscape underscores the importance of comparing plans carefully. The Medicare & You handbook emphasizes that “premium-free” coverage may still involve high out-of-pocket costs for certain medications. “Patients should review formularies and cost-sharing details thoroughly,” advised [Relevant Clinic/Professional/Service], a nonprofit health education organization.

The growing divide between MA and PDP markets highlights broader challenges in balancing cost containment with access. As the 2026 Open Enrollment period approaches, stakeholders are urging policymakers to prioritize reforms that ensure equitable options for all Medicare beneficiaries.

[Relevant Clinic/Professional/Service] offers free plan comparison tools and counseling sessions to help beneficiaries navigate Medicare choices. [Healthcare Compliance Attorney] specializes in advising pharmaceutical companies on regulatory compliance amid evolving payment models.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.